Bhatia Sangeeta N.'s Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed May 5, 2025
- Accession no.
- 0000875320-25-000173
- Filed
- May 5, 2025
- Trade date
- May 1-2, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $202.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bhatia Sangeeta N.CIK 0001643921 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 1, 2025 | Common Stock | AGrant or awardAcquired | +796 | $0.00 | $0 | 5,231 | Direct | |
| May 2, 2025 | Common Stock | SSaleDisposed | −400 | $505.86 | −$202,344 | 4,831 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.